Literature DB >> 22828450

Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.

Keisuke Yoshino1, Koji Nakamura, Yoko Terajima, Akinobu Kurita, Takeshi Matsuzaki, Keiko Yamashita, Masashi Isozaki, Hiroaki Kasukawa.   

Abstract

Recently, a polyethylene glycol (PEG)-modification method for liposomes prepared using pH-gradient method has been proposed. The differences in the pharmacokinetics and the impact on the antitumor effect were examined; however the impact of PEG-lipid molar weight has not been investigated yet. The main purpose of this study is to evaluate the impact of PEG-lipid molar weight against the differences in the pharmacokinetics, the drug-release profile, and the antitumor effect between the proposed PEG-modification method, called the post-modification method, and the conventional PEG-modification method, called the pre-modification method. Various comparative studies were performed using irinotecan as a general model drug. The results showed that PEG-lipid degradation could be markedly inhibited in the post-modification method. Furthermore, prolonged circulation time was observed in the post-modification method. The sustained drug-release was observed in the post-modification method by the results of the drug-releasing test in plasma. Moreover, a higher antitumor effect was observed in the post-modification method. It was also confirmed that the same behaviors were observed in all comparative studies even though the PEG molecular weight was lower. In conclusion, the post-modification method has the potential to be a valuable PEG-modification method that can achieve higher preservation stability of PEG-lipid, prolonged circulation time, and higher antitumor effect with only half the amount of PEG-lipid as compared to the pre-modification method. Furthermore, it was demonstrated that PEG(5000)-lipid would be more desirable than PEG(2000)-lipid since it requires much smaller amount of PEG-lipid to demonstrate the same performances.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22828450     DOI: 10.1016/j.bbamem.2012.07.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Controlling the Biological Fate of Liposomal Spherical Nucleic Acids Using Tunable Polyethylene Glycol Shells.

Authors:  Wuliang Zhang; Cassandra E Callmann; Chad A Mirkin
Journal:  ACS Appl Mater Interfaces       Date:  2021-09-21       Impact factor: 10.383

2.  Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.

Authors:  Kai-Wen Ho; I-J U Chen; Yi-An Cheng; Tzu-Yi Liao; En-Shuo Liu; Huei-Jen Chen; Yun-Chi Lu; Yu-Cheng Su; Steve R Roffler; Bo-Cheng Huang; Hui-Ju Liu; Ming-Yii Huang; Chiao-Yun Chen; Tian-Lu Cheng
Journal:  J Nanobiotechnology       Date:  2021-01-09       Impact factor: 10.435

3.  Bioreducible Poly(Amino Ethers) Based mTOR siRNA Delivery for Lung Cancer.

Authors:  Nishant S Gandhi; Sudhakar Godeshala; Dana-Lynn T Koomoa-Lange; Bhavani Miryala; Kaushal Rege; Mahavir B Chougule
Journal:  Pharm Res       Date:  2018-08-13       Impact factor: 4.200

4.  Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.

Authors:  Federico Perche; Vladimir P Torchilin
Journal:  J Drug Deliv       Date:  2013-03-07

5.  Controlled gene and drug release from a liposomal delivery platform triggered by X-ray radiation.

Authors:  Wei Deng; Wenjie Chen; Sandhya Clement; Anna Guller; Zhenjun Zhao; Alexander Engel; Ewa M Goldys
Journal:  Nat Commun       Date:  2018-07-13       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.